Diagnostic Workup for Testicular Cancer
For a 15-35-year-old male with a painless testicular mass, immediately obtain high-frequency testicular Doppler ultrasound (>10 MHz) and serum tumor markers (AFP, hCG, and LDH) to confirm the diagnosis, followed by radical inguinal orchiectomy if imaging confirms an intratesticular mass suspicious for malignancy 1, 2.
Initial Clinical Assessment
Perform a focused physical examination that includes:
- Bilateral testicular palpation to assess for masses, nodules, enlargement, or induration
- Abdominal examination for lymphadenopathy or masses
- Chest examination and supraclavicular lymph node assessment 1
Diagnostic Imaging Algorithm
Primary Imaging
- High-frequency testicular Doppler ultrasound (>10 MHz) is the initial examination of choice to confirm the presence and characteristics of a testicular mass 1
- This distinguishes intratesticular from extratesticular masses and evaluates for malignancy features (increased vascularization on color Doppler) 3
Staging Imaging (if ultrasound confirms suspicious mass)
- Contrast-enhanced CT scan of chest (including supraclavicular fossa), abdomen, and pelvis 1, 2
- Alternative: MRI of abdomen/pelvis with non-contrast chest CT if iodine-based contrast is contraindicated 1
Additional Imaging (specific circumstances)
Order cerebral imaging (with or without spinal imaging) if any of the following are present:
- Extensive supra-diaphragmatic disease (e.g., lung metastases)
- hCG >5000 IU/L
- Poor-prognosis IGCCCG classification
- Clinical symptoms concerning for brain metastasis 1
Serum Tumor Markers
Obtain before any surgical intervention:
- Alpha-fetoprotein (AFP)
- Human chorionic gonadotropin (hCG)
- Lactate dehydrogenase (LDH)
Critical caveat: Normal tumor markers do NOT exclude testicular cancer—they have low sensitivity but are essential for diagnosis support, staging, and monitoring treatment response 1.
Repeat these markers after orchiectomy to assess for stage IS disease (persistently elevated markers post-surgery) 1.
Emerging Biomarkers
MicroRNA-371a-3p shows higher discriminatory accuracy than conventional markers, but currently remains investigational and should not replace standard tumor markers outside clinical trials due to lack of standardization and limited accessibility 1.
Definitive Diagnosis
Radical inguinal orchiectomy with division of the spermatic cord at the internal inguinal ring is the standard initial treatment and provides definitive histological diagnosis 1, 2, 4.
Testis-Sparing Surgery Considerations
Consider testis-sparing surgery (TSS) ONLY in highly selected cases:
- Indeterminate small testicular masses (<3 cm) on ultrasound with negative tumor markers
- Solitary testis or bilateral tumors
- Normal preoperative testosterone levels
- Requires intraoperative frozen section analysis to confirm benign pathology 1, 5
Important pitfall: TSS has a false-negative rate <10% on frozen section, so radical orchiectomy remains the gold standard for most cases 3.
Alternative Diagnostic Pathway (Advanced Disease Only)
In cases of unequivocal advanced disease with markedly elevated tumor markers, systemic chemotherapy may be initiated without orchiectomy, or after percutaneous biopsy confirmation 2. This is reserved for patients who cannot undergo immediate surgery due to disease burden.
Key Clinical Pitfalls to Avoid
- Never perform trans-scrotal biopsy or scrotal orchiectomy—this violates lymphatic drainage patterns and can alter staging
- Do not delay imaging or referral for painless testicular masses—testicular cancer has >95% cure rates with early diagnosis but requires prompt intervention 1, 6
- Do not rely solely on tumor markers to exclude malignancy—proceed with ultrasound and surgical evaluation regardless of marker levels 1
- Ensure urgent urology referral once ultrasound confirms intratesticular mass—delays in orchiectomy can compromise outcomes
Post-Diagnosis Considerations
After orchiectomy and staging completion:
- Counsel about sperm banking before any additional treatment (chemotherapy/radiation), as fertility may be compromised 6
- Histopathology determines subsequent management (seminoma vs. non-seminomatous germ cell tumor)
- Stage I disease may be managed with surveillance in compliant patients, while metastatic disease requires risk-stratified chemotherapy 1, 4